ENDRA Life Sciences (NASDAQ:NDRA) & Beta Bionics (NASDAQ:BBNX) Financial Review

Beta Bionics (NASDAQ:BBNX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Institutional & Insider Ownership

1.2% of ENDRA Life Sciences shares are held by institutional investors. 0.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Beta Bionics and ENDRA Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	0	4	7	1	2.75
ENDRA Life Sciences	0	0	1	0	3.00

Beta Bionics currently has a consensus target price of $22.5556, suggesting a potential upside of 29.26%. ENDRA Life Sciences has a consensus target price of $50.00, suggesting a potential upside of 1,023.60%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe ENDRA Life Sciences is more favorable than Beta Bionics.

Earnings & Valuation

This table compares Beta Bionics and ENDRA Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$65.12 million	11.65	-$54.76 million	N/A	N/A
ENDRA Life Sciences	N/A	N/A	-$11.51 million	($33.89)	-0.13

ENDRA Life Sciences has lower revenue, but higher earnings than Beta Bionics.

Profitability

This table compares Beta Bionics and ENDRA Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	N/A	N/A	N/A
ENDRA Life Sciences	N/A	-194.14%	-127.89%

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

About ENDRA Life Sciences

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.